Results 141 to 150 of about 2,243,647 (283)

The underlying mechanism of microRNA-21 in gemcitabine resistant breast cancer cells

Zhongguo aizheng zazhi, 2015
Background and purpose: Gemcitabine-based chemotherapy has been shown to have significant activity and favourable safety in metastatic breast cancer patients, but the effectiveness is limited due to drug resistance.
吴振华, 陶中华, 张剑
doaj  

NUP93 facilitates the nuclear import of SOX2 to activate G3BP1 transcription and impairs gemcitabine response in pancreatic cancer

Cell Death and Disease
Gemcitabine is a cornerstone chemotherapeutic for pancreatic ductal adenocarcinoma (PDAC); however, the frequent development of resistance compromises its efficacy and poses a significant challenge to patient prognosis.
Hao Sun, Chenxiao Yang, Juntong Du, Chao Xu, Yao Chen, Jinsuo Chen, Nanxi Yue, Ruining Gong, Zhan Yang   +8 more
doaj   +1 more source

Sensing‐Integrated Patient‐Derived Tumorspheres Predict Chemotherapeutic Efficacy via Local Extracellular pH Dynamics

Small, EarlyView.
The study introduces a 3D sensing‐integrated platform enabling real‐time, non‐invasive monitoring of pH dynamics in patient‐derived PDAC tumorspheres. It revealed distinct extracellular acidification patterns under FOLFIRINOX, gemcitabine, and paclitaxel, correlating with therapeutic efficacy.
Stefania Forciniti, Valentina Onesto, Anna Chiara Siciliano, Helena Iuele, Stefano D'Ugo, Norma Depalma, Cinzia Fasano, Alessandro D'Amuri, Giuseppe Gigli, Marcello G. Spampinato, Loretta L. del Mercato   +10 more
wiley   +1 more source

Thrombocytosis and tumour distribution predict outcome in dogs with hepatocellular carcinoma: A multi‐institutional retrospective analysis

Veterinary Record, EarlyView.
Abstract Background Hepatocellular carcinoma (HCC) is the most common canine hepatobiliary tumour. This study aimed to determine which criteria influenced outcome of HCC in a modern population of dogs across eight institutions. Methods The medical records of 106 dogs with HCC were retrospectively reviewed.
Emily A. Janik, MacKenzie A. Pellin, Dawn M. Clarke   +2 more
wiley   +1 more source

RGDV-modified gemcitabine: a nano-medicine capable of prolonging half-life, overcoming resistance and eliminating bone marrow toxicity of gemcitabine

International Journal of Nanomedicine, 2019
Wenchao Liu1,2, Yujia Mao1,2, Xiaoyi Zhang1,2, Yaonan Wang1,2, Jianhui Wu1,2, Shurui Zhao1,2, Shiqi Peng1,2, Ming Zhao1–3 1Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of ...
Liu W, Mao Y, Zhang X, Wang Y, Wu J, Zhao S, Peng S, Zhao M   +7 more
doaj  

Peptide‐directed nanovehicles enabling tumor‐selective ROS amplification and antitumor immunity

VIEW, EarlyView.
Cancer cells are vulnerable to oxidative stress, yet exploit immune tolerance to escape destruction. In contrast, their metabolic profile is markedly altered to support rapid proliferation, accompanied by elevated production of reactive oxygen species (ROS).
Manuela Calin, Galyna Bila, Ileana Manduteanu, Rostyslav Bilyy   +3 more
wiley   +1 more source

Role of epigenetic regulator EHMT2 in the regulation of gemcitabine resistance in pancreatic cancer

, 2017
[[abstract]]Background: Epigenetic regulation plays an important role in the initiation, promotion and progression of cancers. The alterations of DNA methylation and histone modification are frequently found in pancreatic cancer.
Hung, WC;Pan, MR;Hsu, MC;Chen, LT;Shan, YS
core   +1 more source

Updated EAACI Statement on Drug Hypersensitivity Skin Testing: Methodology and Non‐Irritative Concentrations

Allergy, EarlyView.
ABSTRACT These updated EAACI guidelines aim to standardize skin testing methodologies for both immediate and non‐immediate drug hypersensitivity reactions. For immediate reactions, the optimal testing window is 4–6 weeks post‐reaction; whereas beyond 6 months, false‐negative results increase.
Annick Barbaud, Lene Heise Garvey, Elizabeth Phillips, Michael Ardern‐Jones, Sevim Bavbek, Patrizia Bonadonna, Jean‐Christoph Caubet, Ana‐Maria Copaescu, Valentina Gueli, Jose Julio Laguna, Ricardo Madrigal‐Burgaleta, Francesca Mori, Vito Sabato, Maria J Torres, Knut Brockow   +14 more
wiley   +1 more source

Abstract 2062: Inhibition of STAT3 overcomes gemcitabine resistance in pancreatic cancer cells

, 2017
Gemcitabine is used as the first line treatment of pancreatic ductal adenocarcinoma (PDAC), however, either innate or acquired resistance to gemcitabine limit its therapeutic efficacy.
Yunxiao Meng, Chi-Wei Chen, Wenge Zhu, Ruiqin Wu   +3 more
core   +1 more source

Androgen Receptor Expression in Urothelial Bladder Cancer—A Systematic Review and Meta‐Analysis

ANZ Journal of Surgery, EarlyView.
ABSTRACT Background Bladder cancer is a globally prevalent malignancy with a marked male predominance. Over the past decade, the androgen receptor has been investigated as a potential contributor to bladder cancer pathophysiology. Androgen receptor expression is most commonly assessed via immunohistochemistry, but its association with pathological ...
Alex Buckby, Mandana Gholami, Matthew Hong, Michael O'Callaghan   +3 more
wiley   +1 more source